Travere beefs up rare kidney disease portfolio with up to $1.1B China deal
BioSpace
Travere Therapeutics will gain an exclusive license to the oral BTK inhibitor civorebrutinib, which analysts at Guggenheim Securities said could be "complementary" to the biotech's IgA nephropathy dru
pharminent
June 3, 2026 (Last updated: June 4, 2026)
BioSpace
Travere Therapeutics will gain an exclusive license to the oral BTK inhibitor civorebrutinib, which analysts at Guggenheim Securities said could be “complementary” to the biotech’s IgA nephropathy